留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

《原发性肝癌诊疗指南(2022年版)》更新要点解读

金保 杜顺达 毛一雷 桑新亭

金保, 杜顺达, 毛一雷, 桑新亭. 《原发性肝癌诊疗指南(2022年版)》更新要点解读[J]. 协和医学杂志. doi: 10.12290/xhyxzz.2022-0274
引用本文: 金保, 杜顺达, 毛一雷, 桑新亭. 《原发性肝癌诊疗指南(2022年版)》更新要点解读[J]. 协和医学杂志. doi: 10.12290/xhyxzz.2022-0274
JIN Bao, DU Shunda, MAO Yilei, SANG Xinting. Interpretation on the Updated Points of Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2022-0274
Citation: JIN Bao, DU Shunda, MAO Yilei, SANG Xinting. Interpretation on the Updated Points of Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2022-0274

《原发性肝癌诊疗指南(2022年版)》更新要点解读

doi: 10.12290/xhyxzz.2022-0274
基金项目: 

国家自然科学基金( 81972698)

详细信息
    通讯作者:

    杜顺达,E-mail:dushd@pumch.cn

  • 中图分类号: R735.7

Interpretation on the Updated Points of Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)

Funds: 

National Natural Science Foundation of China (81972698)

  • 摘要: 自《原发性肝癌诊疗规范(2019年版)》发布以来,国内外在肝癌诊治方面涌现出许多新的循证医学高级别证据,尤其是多项符合中国肝癌患者的研究成果相继发表。为进一步规范我国肝癌诊疗行为,国家卫生健康委员会组织全国肝癌领域的多学科专家,再次更新并发布了《原发性肝癌诊疗指南(2022年版)》,旨在实现《"健康中国2030"规划纲要》中总体癌症5年生存率提高15%的目标。本文将对2022版指南的主要更新要点进行解读,以期推动新版指南的广泛传播与实施。
  • [1] Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016[J]. Journal of the National Cancer Center, 2022.
    [2] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020:GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71:209-249.
    [3] 中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版)[J].临床肿瘤学杂志, 2011, 16:929-946.
    [4] 中华人民共和国卫生和计划生育委员会.原发性肝癌诊疗规范(2017年版)[J].中国实用外科杂志, 2017, 37:705-720.
    [5] 中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗规范(2019年版)[J].中华消化外科杂志, 2020, 19:1-20.
    [6] 中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗指南(2022年版)[J].中华消化外科杂志, 2022, 21:143-168.
    [7] 中共中央国务院.《"健康中国2030"规划纲要》[EB/OL].(2016)[2022]. http://www.gov.cn/zhengce/2016

    -10/25/content_5124174.htm.
    [8] Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines:1. Introduction-GRADE evidence profiles and summary of findings tables[J]. J Clin Epidemiol, 2011, 64:383-394.
    [9] Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines:3. Rating the quality of evidence[J]. J Clin Epidemiol, 2011, 64:401-406.
    [10] Andrews JC, Schunemann HJ, Oxman AD, et al. GRADE guidelines:15. Going from evidence to recommendation-determinants of a recommendation's direction and strength[J]. J Clin Epidemiol, 2013, 66:726-735.
    [11] Durieux N, Vandenput S, Pasleau F. OCEBM levels of evidence system[J]. Rev Med Liege, 2013, 68:644-649.
    [12] Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2004, 130:417-422.
    [13] Fan R, Papatheodoridis G, Sun J, et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis[J]. J Hepatol, 2020, 73:1368-1378.
    [14] Johnson PJ, Pirrie SJ, Cox TF, et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers[J]. Cancer Epidemiol Biomarkers Prev, 2014, 23:144-153.
    [15] Best J, Bechmann LP, Sowa JP, et al. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis[J]. Clin Gastroenterol Hepatol, 2020, 18:728-35 e4.
    [16] Caviglia GP, Abate ML, Petrini E, et al. Highly sensitive alpha-fetoprotein, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxyprothrombin for hepatocellular carcinoma detection[J]. Hepatol Res, 2016, 46:E130-E135.
    [17] Berhane S, Toyoda H, Tada T, et al. Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients[J]. Clin Gastroenterol Hepatol, 2016, 14:875-86 e6.
    [18] Huang C, Fang M, Xiao X, et al. Validation of the GALAD model for early diagnosis and monitoring of hepatocellular carcinoma in Chinese multicenter study[J]. Liver Int, 2022, 42:210-223.
    [19] Wang Y, Tian Y. miRNA for diagnosis and clinical implications of human hepatocellular carcinoma[J]. Hepatol Res, 2016, 46:89-99.
    [20] Zhou J, Yu L, Gao X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma[J]. J Clin Oncol, 2011, 29:4781-8.
    [21] Sheng X, Ji Y, Ren GP, et al. A standardized pathological proposal for evaluating microvascular invasion of hepatocellular carcinoma:a multicenter study by LCPGC[J]. Hepatol Int, 2020, 14:1034-47.
    [22] Zhang X, Li J, Shen F, et al. Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2018, 33:347-54.
    [23] Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death:the BRIDGE Study[J]. Liver Int, 2015, 35:2155-66.
    [24] 中国抗癌协会肝癌专业委员会转化治疗协作组.肝癌转化治疗中国专家共识(2021版)[J].中华消化外科杂志, 2021, 20:600-16.
    [25] Kaseb AO, Hasanov E, Cao HST, et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma:a randomised, open-label, phase 2 trial[J]. The Lancet Gastroenterology&Hepatology, 2022, 7:208-18.
    [26] Shi HY, Wang SN, Wang SC, et al. Preoperative transarterial chemoembolization and resection for hepatocellular carcinoma:a nationwide Taiwan database analysis of long-term outcome predictors[J]. J Surg Oncol, 2014, 109:487-93.
    [27] Zhou WP, Lai EC, Li AJ, et al. A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma[J]. Ann Surg, 2009, 249:195-202.
    [28] Singal AG, Lim JK, Kanwal F. AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma:Expert Review[J]. Gastroenterology, 2019, 156:2149-57.
    [29] Sapena V, Enea M, Torres F, et al. Hepatocellular carcinoma recurrence after direct-acting antiviral therapy:an individual patient data meta-analysis[J]. Gut, 2022, 71:593-604.
    [30] Kulik L, Heimbach JK, Zaiem F, et al. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation:A systematic review and meta-analysis[J]. Hepatology, 2018, 67:381-400.
    [31] Lee S, Kim KW, Song GW, et al. The Real Impact of Bridging or Downstaging on Survival Outcomes after Liver Transplantation for Hepatocellular Carcinoma[J]. Liver Cancer, 2020, 9:721-33.
    [32] Mazzaferro V, Citterio D, Bhoori S, et al. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL):a randomised, controlled, phase 2b/3 trial[J]. The Lancet Oncology, 2020, 21:947-56.
    [33] Mehta N, Guy J, Frenette CT, et al. Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria:A Multicenter Study[J]. Clin Gastroenterol Hepatol, 2018, 16:955-64.
    [34] Qu S, Worlikar T, Felsted AE, et al. Non-thermal histotripsy tumor ablation promotes abscopal immune responses that enhance cancer immunotherapy[J]. J Immunother Cancer, 2020, 8.
    [35] Greten TF, Mauda-Havakuk M, Heinrich B, et al. Combined locoregional-immunotherapy for liver cancer[J]. J Hepatol, 2019, 70:999-1007.
    [36] Mizukoshi E, Yamashita T, Arai K, et al. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma[J]. Hepatology, 2013, 57:1448-57.
    [37] Slovak R, Ludwig JM, Gettinger SN, et al. Immuno-thermal ablations-boosting the anticancer immune response[J]. J Immunother Cancer, 2017, 5:78.
  • 加载中
计量
  • 文章访问数:  4
  • HTML全文浏览量:  0
  • PDF下载量:  1
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-05-13
  • 录用日期:  2022-05-27
  • 网络出版日期:  2022-06-23

目录

    /

    返回文章
    返回

    尊敬的审稿专家、作者及读者朋友,因特殊原因,网站于6月30日24时至7月1日24时为镜像,在此期间登录及上传和更新功能将受到影响,给您带来不便,敬请谅解。